1.9807.26% ( -0.155 )
Delay Closed: Nov 20, 16:08:00Valuation
Current ValuationThe current P/E ratio is -2.28, within the reasonable range, cheaper than 74.16% of the time in the past 5 years, and the industry ranks 28/78, the industry Median -4.64.
-2.28xP/E
HK$2.14Stock price
HK$-0.93Earnings per share
-2.28xP/E
Stock priceHK$2.14Earnings per shareHK$-0.93
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.39x
- Typical range
- -2.69x–-0.99x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0145290435580
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -51.56x | 66.53% | HK$57.41B |
09688HKZAI LAB | -14.03x | 11.94% | HK$21.83B |
01877HKJUNSHI BIO | -31.71x | 83.59% | HK$14.57B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
02616HKCSTONE PHARMA-B | -19.87x | 1.09% | HK$9.59B |
06855HKASCENTAGE | -5.46x | 19.15% | HK$9.23B |
07666HKMETIS TECHBIO-P | -21.34x | 96.67% | HK$8.69B |
09606HKDUALITYBIO-B | -5.06x | 85.35% | HK$8.38B |
01952HKEVEREST MED | -131.16x | 284.92% | HK$8.14B |
02493HKMABWELL-B | -6.36x | -- | HK$7.78B |
02595HKGENFLEET-B | -4.64x | 66.07% | HK$7.03B |
06938HKRIBOLIFE-B | -34.62x | 29.56% | HK$6.76B |
02335HKMICOT PHARMA-B | -14.46x | 37.52% | HK$6.07B |
09887HKLEADS BIOLABS-B | -19.46x | 3.57% | HK$5.98B |
02171HKCARSGEN-B | -56.48x | 52.33% | HK$5.80B |
09966HKALPHAMAB-B | -25.37x | -- | HK$5.14B |
00775HKCKLIFE SCIENCES | -74.28x | -- | HK$4.81B |
01672HKASCLETIS-B | -6.80x | 78.53% | HK$4.63B |
02256HKABBISKO-B | -8.22x | 814.43% | HK$4.42B |
06872HKTENNOR THERAP-B | -24.29x | -- | HK$3.90B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
